Virtual play therapy aims to boost motor skills and social life in young leukemia survivors
NCT ID NCT07522905
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a 12-week virtual buddy-movement therapy for children aged 5 to 12 who have finished treatment for acute lymphoblastic leukemia. The program pairs each child with a healthy buddy for twice-weekly movement sessions designed to improve motor skills, coordination, and quality of life. Researchers will measure changes in motor proficiency and emotional/social functioning, comparing a group that does the therapy to a control group that does not.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Virtual buddy-movement therapy (behavioral intervention)
- What this could lead to
- If it works, this could offer a fun, social way to help children recovering from leukemia improve their movement, coordination, and emotional well-being.
- What could go wrong
- This is a small early study with only 24 participants, so results may not apply to all children. The therapy is behavioral, so benefits depend on participation and may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: 5-12 years * Diagnosis: acute lymphoblastic leukemia in complete remission * First-line treatment of acute lymphoblastic leukemia according to the treatment protocol * BUDDY - a healthy friend aged 5-12 years Exclusion Criteria: * Participation in the movement program less than 80%
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institute of Children´s Diseases
RECRUITINGBratislava, 83340, Slovakia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells aim to wipe out stubborn leukemia
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- The immune cells that could make stem cell transplants work better
- Aloe vera mouthwash tested against chemotherapy mouth sores
- Can a Chemo-Only prep beat radiation for childhood leukemia transplants?
- Can a targeted drug hit the mark in Hard-to-Treat blood cancers?